SPan-1 and Exocrine Pancreatic Carcinoma. The Clinical Role of a New Tumor Marker

Carter D.C. Aetiology and epidemiology of pancreatic and periampullary cancer. In: Trede M. , Carter D.C. , eds. Surgery of the pancreas. Edinburgh: Churchill Livingstone Publisher, 1993; 383–97.

Trede M. , Wendl K. , Richter A. Pancreatic carcinoma – Conclusions and prospects. Langenbecks Arch Chir Suppl Kongressbd 1998; 115: 411–20.

Hamori J. , Arkosy P. , Lenkey A. , Sapy P. The role of different tumor markers in the early diagnosis and prognosis of pancreatic carcinoma and chronic pancreatitis. Acta Chir Hung 1997; 36: 125–7.

Matsumotu S. , Harada H. , Tanaka J. Evaluation of cytology and tumor markers of pure pancreatic juice for the diagnosis of pancreatic cancer at early stages. Pancreas 1994; 9: 741–7.

Niederau C. , Grendell J.H. Diagnosis of pancreatic carcinoma. Imaging techniques and tumor markers. Pancreas 1992; 7: 66–86.

Ban T. , Imai K. , Yachi A. Immunohistological and immunochemical characterization of a novel pancreatic cancer-associated antigen MUSE11. Cancer Res 1989; 49: 7141–6.

Basso D. , Panozzo M.P. , Fabris C. Does serum CAR-3 play a role in pancreatic cancer diagnosis? Oncology 1991; 48: 22–5.

Ching C.K. , Holmes S.W. , Holmes G.K.T. Blood-group sialyl-Tn antigen is more specific than Tn as a tumor marker in the pancreas. Pancreas 1994; 9: 698–702.

Ching C.K. , Holmes S.W. , Holmes G.K.T. Comparison of two sialosyl-Tn binding monoclonal antibodies (MLS102 and B72.3) in detecting pancreatic cancer. Gut 1993; 34: 1722–5.

Flomen R. , Moss M. , Grant D. The protein core of the NCA-related pancreatic adenocarcinoma-associated antigen (DD9-Ag) is NCA-50. Pancreas 1993; 8: 166–70.

Hyöty M. , Hyöty H. , Aaran R.K. Tumor antigens CA 195 and CA 19.9 in pancreatic juice and serum for the diagnosis of pancreatic carcinoma. Eur J Surg 1992; 158: 173–9.

Ho J.J.L. , Bi N. , Yan P. Characterization of new pancreatic cancer-reactive monoclonal antibodies directed against purified mucin. Cancer Res 1991; 51: 372–80.

Ho J.J.L. , Kim Y.S. Serological pancreatic tumor markers and the MUC1 apomucin. Pancreas 1994; 9: 674–91.

Kawa S. , Kato M. , Oguchi H. Preparation and partial characterization of a pancreatic cancer-associated glycoprotein expressing CA 50. Scand J Gastroent 1991; 26: 1307–18.

Kozwich D.L. , Kramer L.C. , Mielicki W.P. Application of cancer procoagulant as an early detection tumor marker. Cancer 1994; 74: 1367–76.

Ohshio G. , Manabe T. , Watanabe Y. Comparative studies of DU-PAN-2, carcinoembryonic antigen, and CA 19.9 in the serum and bile of patients with pancreatic and biliary tract diseases: evaluation of the influence of obstructive jaundice. Am J Gastroenterol 1990; 85: 1370–6.

Parker N. , Makin C.A. , Ching C.A. A new enzyme-linked lectin/mucin antibody sandwich assay (CAM 17.1/WGA) assessed in combination with CA 19.9 and peanut lectin binding assay for the diagnosis of pancreatic cancer. Cancer 1992; 70: 1062–8.

Prat M. , Medico E. , Rossino P. Biochemical and immunological properties of the human carcinoma-associated CAR-3 epitope defined by the monoclonal antibody AR-3. Cancer Res 1989; 49: 1415–21.

Rubin D. , Warshaw A.L. , Southern J.F. Expression of CA 15.3 protein in the cyst contents distinguishes benign from malignant pancreatic mucinous cystic neoplasms. Surgery 1994; 115: 52–5.

Sinn H.P. , Brown S.A. , Thompson J.S. Characterization of new monoclonal antibodies directed against normal human exocrine pancreas and pancreatic adenocarcinomas. Pancreas 1993; 8: 279–88.

Takada M. , Yamamoto M. , Saitoh Y. The significance of CD44 in human pancreatic cancer: I. high expression of CD44 in human pancreatic adenocarcinoma. Pancreas 1994; 9: 748–52.

Gullo L. CA 19.9: the Italian experience. Pancreas 1994; 9: 717–9.

Safi F. , Schlosser W. , Falkenreck S. , Beger H.G. Prognostic value of CA 19–9 serum course in pancreatic cancer. Hepatogastroenterology 1998; 45: 253–9.

Ritts R.E. , Pitt H.A. CA 19–9 in pancreatic cancer. Surg Oncol Clin N Am 1998; 7: 93–101.

Satake K. , Takeuchi T. Comparison of CA 19.9 with other tumor markers in the diagnosis of cancer of the pancreas. Pancreas 1994; 9: 720–4.

Forsmark C.E. , Lambiase L. , Vogel S.B. Diagnosis of pancreatic cancer and prediction of unresectability using the tumor-associated antigen CA 19.9. Pancreas 1994; 9: 731–4.

Malesci A. , Montorsi M. , Mariani A. Clinical utility of the serum CA 19.9 test for diagnosing pancreatic carcinoma in symptomatic patients: a prospective study. Pancreas 1992; 7: 497–502.

Ritts R.E. Jr. , Nagorney D.M. , Jacobsen D.J. Comparison of preoperative serum CA 19.9 levels with results of diagnosing imaging modalities in patients undergoing laparotomy for suspected pancreatic or gallbladder disease. Pancreas 1994; 9: 707–16.

Satake K. , Takeuchi T. , Homma T. CA 19.9 as a screening and diagnostic tool in symptomatic patients: the Japanese experience. Pancreas 1994; 9: 703–6.

Sperti C. , Pasquali C. , Catalini S. CA 19.9 as a prognostic index after resection for pancreatic cancer. J Surg Oncol 1993; 52: 137–41.

Beretta E. , Malesci A. , Zerbi A. Serum CA 19.9 in the post-surgical follow-up of patients with pancreatic cancer. Cancer 1987; 60: 2428–31.

Steinberg W. The clinical utility of the CA 19.9 tumor-associated antigen. Am J Gastroenterol 1990; 85: 350–5.

Yasue M. , Sakamoto J. , Teramukai S. Prognostic values of preoperative and postoperative CEA and CA 19.9 levels in pancreatic cancer. Pancreas 1994; 9: 735–40.

Ho J.J.L. , Chung Y. , Fujimoto Y. Mucin-like antigens in a human pancreatic cell line identified by murine monoclonal antibodies SPan-1 and YPan-1. Cancer Res 1988; 48: 3924–31.

Itai S. , Arii S. , Tobe R. Significance of 2–3 and 2–6 sialylation of Lewis A antigen in pancreas cancer. Cancer 1988; 61: 775–87.

Von Rosen A. , Linder S. , Harmenberg U. Serum levels of CA 19.9 and CA 50 in relation to Lewis blood cell status in patients with malignant and benign pancreatic disease. Pancreas 1993; 8: 160–5.

Vestergaard E.M. , Hein H.O. , Meyer H. Reference values and biological variation for tumor marker CA 19–9 in serum for different Lewis and secretor genotypes and evaluation of secretor and Lewis genotyping in a Caucasian population. Clin Chem 1999; 45: 54–61.

Takeda S. , Nakao A. , Ichihara T. Serum concentration and immunohistochemical localization of SPan-1 antigen in pancreatic cancer. A comparison with CA 19.9 antigen. Hepatogastroenterology 1991; 38: 143–8.

Kawa S. , Tokoo M. , Oguchi H. Epitope analysis of SPan-1 and DUPAN-2 using synthetized glycoconjugates sialyllact-N-fucopentaose II and sialyllact-N-tetraose. Pancreas 1994; 9: 692–7.

Kiriyama S. , Hayakawa T. , Kondo T. Usefulness of a new tumor marker, SPan-1, for the diagnosis of pancreatic cancer. Cancer 1990; 65: 1557–61.

Praderi R.C. History of pancreatic surgery. In: Trede M. , Carter D.C. , eds. Surgery of the pancreas. Edinburgh: Churchill Livingstone, 1993; 3–15.

Jeekel J. Chemotherapy and radiotherapy in the treatment of pancreatic cancer. In: Trede M. , Carter D.C. , eds. Surgery of the pancreas. Edinburgh: Churchill Livingstone, 1993; 515–8.

Riker A. , Libutti S.K. , Bartlett D.L. Advances in the early detection, diagnosis, and staging of pancreatic cancer. Surg Oncol 1997; 6: 157–69.

Kuno N. , Kurimoto K. , Fukushima M. Effectiveness of multivariate analysis of tumor markers in diagnosis of pancreatic carcinoma: a prospective study in multiinstitutions. Pancreas 1994; 9: 725–30.

Satake K. , Chung Y.S. , Umeyama K. The possibility of diagnosing small pancreatic cancer (less than 4 cm) by measuring various serum tumor markers. Cancer 1991; 68: 149–62.

Satake K. , Chung Y.S. , Yokomatsu H. Various tumor markers for small pancreatic cancer with special reference to the present status of pancreatic cancer in Japan and our experience over the past 2 years. Pancreas 1991; 6: 234–41.

Athlin L. , Blind P.J. , Eriksson S. The value of routine biochemical tests in discriminating between malignant and benign pancreatic tumours. HPB Surgery 1991; 4: 147–55.

Benini L. , Cavallini G. , Zordan D. A clinical evaluation of monoclonal (CA 19.9, CA 50, CA 12.5) and polyclonal (CEA, TPA) antibody-defined antigens for the diagnosis of pancreatic cancer. Pancreas 1988; 3: 61–6.

Böttger T. , Weber W. , Gaedertz C. Wertigkeit der präoperativen Diagnostik zur Beurteilung der Tumorausdehnung bei ductalen Pankreascarcinomen. Langenbecks Arch Chir 1990; 375: 33–8.

Safi F. , Roscher R. , Bittner R. High sensitivity and specificity of CA 19.9 for pancreatic carcinoma in comparison to chronic pancreatitis. Serological and immunohistochemical findings. Pancreas 1987; 4: 398–403.

Wakabayashi T. , Sawabu N. , Takemori Y. Diagnostic signficance of cancer-associated carbohydrate antigen (CA 19.9) concentrations in pancreatic juice: analysis in pure pancreatic juice collected by endoscopic aspiration and immunohistochemical study in chronic pancreatitis. Pancreas 1993; 8: 151–9.

Del Favero G. , Fabris C. , Plebani M. CA 19.9 and carcinoembryonic antigen in pancreatic cancer diagnosis. Cancer 1986; 57: 1576–9.

Ichihara T. , Nagura H. , Nakao A. Immunolistochemical localization of CA 19.9 and CEA in pancreatic carcinoma and associated diseases. Cancer 1988; 61: 324–33.

Meduri F. , Losacco L. , Diana F. L.A.I. test e markers tumorali (CA 19.9 e TPA). Analisi e prospettive di applicazione nella diagnosi di carcinoma pancreatico. Chirurgia 1988; 1: 305–8.

Pasanen P.A. , Eskelinen M. , Partanen K. Clinical evaluation of a new serum tumor marker CA 242 in pancreatic carcinoma. Br J Cancer 1992; 65: 731–4.

Sessa F. , Bonato M. , Frigerio B. Ductal cancers of the pancreas frequently express markers of gastrointestinal epithelial cells. Gastroenterology 1990; 98: 1655–65.

Ventrucci M. , Ubalducci G.M. , Cipolla A. , Panella M.A. , Ligabue A. Serum CA 242: the search for a valid marker of pancreatic cancer. Clin Chem Lab Med 1998; 36: 179–84.

Uchino R. , Kanemitsu K. , Obayashi H. Carcinoembryonic antigen (CEA) and CEA-related substances in the bile of patients with biliary diseases. Am J Surg 1994; 167: 306–8.

Zamcheck N. , Martin E.W. Factors controlling the circulating CEA levels in pancreatic cancer: some clinical correlations. Cancer 1981; 47: 1620–7.

Yamaguchi K. , Enjoji M. , Tsuneyoshi M. Pancreatoduodenal carcinoma: a clinicopathologic study of 304 patients and immunohistochemical observation for CEA and CA 19.9. J Surg Oncol 1991; 47: 148–54.

Rhodes J.M. Usefulness of novel tumour markers. Ann Oncol 1999; 10(S4): 118–21.

Lamerz R. Role of tumour markers, cytogenetics. Ann Oncol 1999; 10(S4): 145–9.